Created with Sketch.
The MTPConnect Podcast
19 minutes | 3 days ago
Partnering in the age of COVID: Real World Tips from Dimerix
In this episode we take you to our recent Collaboration and Skills Summit where we brought together a panel of industry experts to share their tips and experiences on how to maximise virtual partnering success at biotech conferences and meetings. You will hear from Dr Nina Webster, the Managing Director & CEO of Dimerix Limited who shares the highs and lows of forming relationships and doing deals online in the age of COVID-19.If you are seeking new strategic partnerships for funding or collaboration this episode is for you.
23 minutes | 19 days ago
Are you a medtech or pharma startup? The 2021 Australian Technologies Competition wants you!
This week’s edition of the MTPConnect podcast checks in with the Australian Technology Competition - Australia's national Competition, late-stage accelerator and partnerships program designed to identify and accelerate homegrown scaleups with global potential. Last year, Electrogenics Laboratories won the Australian Technology Company of the Year and also took out the Medtech and Pharma Award, for developing its MOSkin Sensor Technologies, an affordable wireless radiation sensor technology that precisely measures radiation skin doses. Host Shannan Osrin meets their Executive Chairman Kim Lyle who looks back on the impact of the win and the experiences gained, and shares tips on start-up success. Also joining the discussion is Patrick Mooney, Chair of Impact Tech Ventures, the organiser of the Competition. Now in its 11th year, the Competition is supported by the Department of Industry, Science, Energy and Resources, MTPConnect and other Industry Growth Centres, and industry partners. Entries are now open for the Competition in eleven categories, including the Medtech & Pharma Award, and close on 10 May 2021.
25 minutes | a month ago
Part 2: The Inflazome Story - the research, the deal and scientists that made it happen
Tune in for part 2 of our 100th episode special, following our chat with Professor Kate Schroder, head of the Inflammasome Laboratory and Director of the Centre for Inflammation and Disease Research at the Institute for Molecular Bioscience (IMB), University of Queensland and Professor Ian Henderson, the Director of IMB. We explore the story behind the milestone research discovery that could lead to a treatment for conditions like Parkinson’s and Alzheimer’s disease, Motor Neurone Disease – even asthma. The innovation was developed out of the UQ, in partnership with Trinity College in Dublin. And the start-up company spawned by the research – Inflazome - was recently acquired by Roche in a deal worth around $600 million, making it one of Australia’s largest ever biotech deals. We also explore the broader work of IMB and the international collaborative approach underpinning its research successes.
26 minutes | a month ago
The Inflazome Story: the research, the deal and scientists that made it happen
Happy 100th episode subscribers! We bring you part 1 of a special double episode following our chat with Professor Kate Schroder, head of the Inflammasome Laboratory and Director of the Centre for Inflammation and Disease Research at the Institute for Molecular Bioscience (IMB), University of Queensland and Professor Ian Henderson, the Director of IMB. We explore the story behind the milestone research discovery that could lead to a treatment for conditions like Parkinson’s and Alzheimer’s disease, Motor Neurone Disease – even asthma. The innovation was developed out of the UQ, in partnership with Trinity College in Dublin. And the start-up company spawned by the research – Inflazome -- was recently acquired by Roche in a deal worth around $600 million, making it one of Australia’s largest ever biotech deals. We also explore the broader work of IMB and the international collaborative approach underpinning its research successes.
33 minutes | a month ago
Spotlight: Artrya Marches to its Own Beat
In this week’s episode, we chat to WA-based digital health company Artrya’s Co-Founders - CEO John Konstantopoulos and Chairman John Barrington AM - about developing their heart disease detection application, which uses radiology and Artificial Intelligence to more accurately identify patients at risk of Coronary Artery Disease without invasive surgery in a matter of minutes. The ‘software as a service’ solution will also guide cardiologists to deliver more effective treatment. Artrya received funding through MTPConnect’s BioMedTech Horizons program. After starting up two years ago, Artrya have already received TGA registration and are poised to launch pilot programs in WA medical practices. In this episode they reveal more about their mission to save lives and take their solution around the globe.
57 minutes | 2 months ago
Adaptive regulation for digital health technologies - a pathway for industry. Listen to Our Seminar!
For this episode, we take you to our monthly seminar which is hosted by MTPConnect’s Andrew Bowskill and facilitated by Dr Lisette Pregelj (The University of Queensland). We bring together an expert panel to discuss the opportunities and challenges of embracing Australia’s adaptive regulation process when developing digital health technologies. Hear from Tracey Duffy (Therapeutic Goods Administration), Helen Souris (Cardihab), Dr Rob Grenfell (CSIRO) and Bronwyn Le Grice (ANDHealth) about the value of regulatory approval, the pitfalls and plans digital health innovators need to consider and tips for navigating the TGA processes! This is a must listen to episode for all the Australian digital health entrepreneurs preparing to commercialise their product and take it to markets around the world. You can also download our report ‘Adaptive Regulation for Digital Health’ from the MTPConnect website.
34 minutes | 2 months ago
Making it Happen: Modern Manufacturing and Medical Products
For this episode, we explore the Australian Government’s focus on modern manufacturing and Medical Products. The Minister for Industry, Science and Technology, The Hon. Karen Andrews MP recently announced that funding is now available for Medical Products manufacturing under the $1.3 billion Modern Manufacturing Initiative (MMI). The Minister also released the Medical Products road map which will guide government and industry investment under the MMI. To discuss these developments in more detail we are joined by Nick Purtell, General Manager, Industry Engagement Branch, in the Manufacturing Division of the Department of Industry, Science, Energy and Resources. Nick also provides information on applying for the MMI funding currently available in two streams - Translation and Integration streams. The round closes on 29 March 2021. The MMI presents an opportunity for Australia’s MTP sector to step-up and secure funding to boost our unique manufacturing capabilities.
28 minutes | 2 months ago
Improving Workforce Skills: Supporting the Development Pathway For Emerging Digital Health Entrepreneurs
For this episode, we explore and navigate the development pathway for emerging digital health entrepreneurs with our REDI partner, ANDHealth, Australia’s national digital health initiative. Supported by MTPConnect’s REDI initiative, ANDHealth is providing a range of popular bespoke training programs to build commercialisation capabilities for founders, whether they are medical professionals, software specialists or business owners.ANDHealth CEO & Managing Director Bronwyn Le Grice is joined by Macuject Founder Dr Devinder Chauhan to chat about the bespoke ANDHealth training programs designed to build commercialisation capabilities for founders in the rapidly growing digital health space. Bronwyn discusses why ANDHealth’s programs address common pitfalls and knowledge gaps that exist for digital health companies. As a retinal ophthalmologist Devinder explains how professional development designed just for digital health entrepreneurs helped him grow from a medical expert to a medical innovator. He shares lessons learned by participating in ANDHealth’s three-week Masterclass Program, and how it’s changed his approach and mindset when seeking investors and managing his company. Macuject’s research, developing a software to help doctors make treatment decisions for macular disease, is supported by MTPConnect’s BioMedTech Horizons program, an initiative of the Medical Research Future Fund.
30 minutes | 2 months ago
Spotlight: Starpharma’s COVID-19 Nasal Spray for UK & Europe
Melbourne based-Starpharma CEO Dr Jackie Fairley joins the MTPConnect Podcast this week to share the full story behind the fast track development of VIRALEZE™, an antiviral nasal spray for COVID-19 just registered in Europe and soon to be available in the EU and UK to complement vaccines and other preventative measures. Jackie shares how MRFF funding from MTPConnect’s Biomedical Translation Bridge (BTB) Program came through at the right time to support the research and development of the spray against important respiratory viruses. She also outlines Starpharma’s work with global pharmaceutical giants to develop new medical products based on dendrimers that are used to improve pharmaceuticals, to reduce toxicities and enhance their performance.
85 minutes | 3 months ago
Collaboration for Innovation: CRC-P Grants for Medical Products Manufacturing. Listen To Our Webinar!
We’re patching you into our first seminar series webinar for 2021 about the opportunity to access Round 11 of Cooperative Research Centres Projects (CRC-P) Grants which provides funding for short-term industry-led research collaborations. Our guests Martin Dent and Adrian March from the Department of Industry, Science, Energy and Resources (DISER) and Shay Chalmers from Strategic Engineering Australia share important insights and advice on preparing applications, why collaboration is important, the challenges of advanced manufacturing for medical products and more. Adrian provides an update on the Australian Government’s Modern Manufacturing Strategy and other avenues for funding of manufacturing-related projects, including the Modern Manufacturing Initiative. The session was led by MTPConnect’s Director of Stakeholder Engagement NSW Dr Duncan Macinnis.
27 minutes | 3 months ago
Navigating Regulatory Pathways: Orthocell Moves Into New Markets
In this week’s podcast, we travel to Perth to talk to regenerative medicine company Orthocell about gaining TGA, EU and US FDA approval to market its CelGro collagen membrane for dental and jaw bone surgeries. CelGro is a collagen scaffold that supports tissue reconstruction and repair. Orthocell CEO Paul Anderson discusses the regulatory approach for markets in Australia, Europe and the United States, and the setup of their dedicated and licenced GMP manufacturing facility in Perth. He shares some words of advice for medtech and medical device entrepreneurs too. This is a must-listen to episode for SMEs and start-ups keen to learn more about commercialising regenerative medicines!
26 minutes | 3 months ago
Establishing a Regional Medtech Network out of Newcastle
This week the podcast travels to the city of Newcastle to find out why a new regional medtech industry network has sprung up in the Hunter Central Coast Region, a location synonymous with coal. Trevor John, Director of Regional Development and Executive Officer and Kate O’Mara, Director Special Projects from the Regional Development Australia Hunter Committee join the podcast team to discuss the companies behind the MedTeCCH network, how COVID-19 prompted a re-think around advanced manufacturing capabilities, and the challenge to create more innovation-driven jobs. To join the network or learn more about medtech capabilities in the region, visit https://www.medtecch.org.au/.
33 minutes | 3 months ago
Testing times – Aussie medical device breaks into US market
Brisbane-based Ellume Health’s Founder and CEO Dr Sean Parsons joins the MTPConnect podcast this week to share the full story behind developing the first #COVID-19 Home Test to be given FDA Emergency Use Authorisation in the United States. Ellume recently signed a $300 million deal with the US government to supply the over-the-counter diagnostic which uses smart-device connectivity and ramping-up Australian manufacturing will be critical to meeting demand. This is a must-listen episode for medtech innovators keen to understand more about commercialisation success in America. Sean shares his ten-year journey from physician to founder, including tips for fellow entrepreneurs and his views on how to boost sovereign capabilities by growing medical products manufacturing in Australia.
62 minutes | 4 months ago
The Lowdown: Funding for Two Research Centres in Diabetes & Cardiovascular Disease Through The Targeted Translation Research Accelerator (TTRA) Initiative
To stimulate collaboration across industry, research and clinical organisations we’re allocating $20 million to support the establishment of two new Research Centres through the Targeted Translation Research Accelerator (TTRA) initiative for diabetes and cardiovascular disease, supported by the Medical Research Future Fund. MTPConnect is calling for Expressions of Interest (EOI) to establish one centre focused on diabetes-associated complications and the other on cardiovascular disease-associated complications and each funded for up to $10 million over four years. The program has the potential to transform diabetes and cardiovascular disease outcomes and reduce the burden of disease on patients, families and the community. This Information Session provides valuable information to those considering submitting an EOI. Dr Dan Grant, MTPConnect Managing Director & CEO discusses the Research Centres opportunity. Lauren Kelly, MTPConnect Senior Director TTRA program and Dr Mana Liao, MTPConnect Director TTRA program outline the priority areas, submission process and provide relevant information about preparing an application. You will also hear from our TTRA Expert Advisory Board Chair Professor Ian Frazer AC FRS who contributes to the question time.
80 minutes | 4 months ago
Funding for Diabetes & Cardiovascular Disease On Offer Through The Targeted Translation Research Accelerator (TTRA) Initiative
The Targeted Translation Research Accelerator (TTRA) initiative for diabetes and cardiovascular disease, supported by the Medical Research Future Fund, is calling for Expressions of Interest (EOI) for the first round of Research Projects funding. The program is making available $18 million to support translational Research Projects that have the potential to transform diabetes and cardiovascular disease outcomes and reduce the burden of disease on patients, families and the community – with up to $6 million available in this first round. This Information Session provides valuable information to those considering submitting an EOI. Dr Dan Grant, MTPConnect Managing Director & CEO discusses the Research Projects opportunity. Lauren Kelly, MTPConnect Senior Director TTRA program and Dr Mana Liao, MTPConnect Director TTRA program outline the priority areas, submission process and provide relevant information about preparing an application. You will also hear from our TTRA program partners who will be providing mentoring and commercialisation advice to applicants and those receiving funding:ANDHealth’s Co-Founder & Chief Product Officer Grace LethleanMDPP’s National Program Manager Olivia White and;UniQuest’s Senior Director QEDDI Dr Andrew Harvey
25 minutes | 5 months ago
Developing Medical Countermeasures for Pandemic Preparedness
While Australia is getting on top of COVID-19 and Britain begins vaccinating frontline healthcare workers, the virus is still raging in the US, Europe, and many parts of the world. It all underscores the critical importance of ongoing pandemic preparedness – for policy makers, industry and the community. To hear more about Australia’s efforts, we meet Dr Felicia Pradera who leads the DMTC Medical Countermeasures (MCM) program, which involves harnessing Australia’s capabilities to develop leading-edge, advanced technologies and to direct and deploy skills into activities that support Australian defence, health and national security outcomes. Medical Countermeasures include vaccines, therapeutics and diagnostics for the protection of military and civilian personnel against Chemical, Biological and Radiological threats, emerging infectious diseases and pandemics. They have just launched the National Health Security Resilience Assessment (open until 31 May 2021) to evaluate Australia’s research, product development and manufacturing capability in six priority areas - MCM, Medical Devices, PPE, Modelling and Simulation, Hazard Management and Sensing Systems. Find out why they need input from the MTP sector to help provide a national picture of Australia’s capability and capacity in the health security ecosystem.
30 minutes | 5 months ago
The Future of Digital Security in Australian Medtech - Lives Depend On It
Digital evolution is the central enabling megatrend of the MTP sector. As healthcare incorporates more and more digital solutions, its important to get cybersecurity right. Lives depend on it. So how do we secure the digital safety and security of Australian medical technology and is the sector too complacent? MTPConnect’s Managing Director & CEO Dr Dan Grant tackled that question in his keynote at the Medical Technology Association of Australia (MTAA)’s Cyber Security Forum, in November 2020. MTPConnect was pleased to be a sponsor and support further discussion in this area. Many thanks to the MTAA for championing this issue and thanks to CSIRO’s Director of Health and Biosecurity Dr Rob Grenfell for facilitating the session.
68 minutes | 6 months ago
Show Me The Money: Preparing Successful Commercialisation Funding Applications. Listen to Our Webinar!
We’re patching you into our November 2020 Seminar Series webinar about how to craft a successful commercialisation funding application. Hear valuable tips from communications specialist and grant writer Rebecca Colless from gemaker, experienced grant assessor Dr Andy Gearing from BioComm Squared and Professor Kevin Pfleger from UWA who shares his academic and commercial experience, highlighting key differences between research and commercialisation applications. MTPConnect’s Dr Dan Grant brings insights from his own research career and administering MTPConnect’s multiple translation funding programs. They explore the steps to developing a well-executed application, share their experiences and reveal why it is so important to get the story right. The session was led by MTPConnect’s Director of Stakeholder Engagement for WA Dr Tracey Wilkinson. This episode will be of interest to researchers, research offices, start-ups & SMEs.
31 minutes | 6 months ago
World Antimicrobial Awareness Week: OUTBREAK Report On Superbugs
Happy bonus episode listeners! To mark World Antimicrobial Awareness Week, the MTPConnect podcast team caught up with OUTBREAK Managing Director & Co-founder Associate Professor Branwen Morgan from the University of Technology Sydney and Distinguished Professor Antoine van Oijen, who is OUTBREAK’s Deputy Managing Director and Director of Health Programs from the University of Wollongong, to talk about their new economic report on the impact of antimicrobial resistance in Australia released this week which shines a light on the multi-million dollar cost of drug-resistant infections and connects the overuse and misuse of antibiotics to the health and economic impact of a single disease. OUTBREAK is a national consortium whose analysis used big data and Artificial Intelligence to highlight how urinary tract infections (UTIs) are becoming more persistent and harder to treat, resulting in more people being admitted to hospital where they require longer stays and more costly medicines. Each year UTIs alone lead to 2.5 million GP appointments, 100K emergency visits and 75K hospital stays!. OUTBREAK is a member of MTPConnect’s AAMRNet, Australia’s first Antimicrobial Resistance Network launched in October 2020. The report is available to download at OUTBREAK Project’s website: https://outbreakproject.com.au/antimicrobial-resistance-publications/utis-economic-report/. For more information on AMR, follow Twitter for updates at @AAMRNet_ and @OneHealthAU.
27 minutes | 6 months ago
Improving Workforce Skills: GSK Australia Joins REDI with new PhD Graduate Innovation Program!
For this episode, we’re exploring the incredible benefits that can flow from connecting PhD graduates with industry. By giving researchers real-world experiences in research-intensive organisations, we can drive better commercialisation outcomes. And it’s exactly what we’re doing as a core component of our ‘Researcher Exchange and Development within Industry’ (REDI) program - in partnership with pharmaceutical company GSK. GSK is one of the largest pharmaceutical companies in the world researching, developing and manufacturing innovative pharmaceutical medicines, vaccines and consumer healthcare products. The company has operations in Australia which employ 1,500 people in Sydney and Melbourne. GSK Australia has developed a new PhD graduate program to facilitate the cross pollination of scientific, academic research expertise with that of the Pharmaceutical Industry. The MTPConnect podcast team of Caroline Duell and Dr Rebecca Tunstall speak to GSK’s Head of Human Resources - Australia & New Zealand David Fitz-Gerald and GSK’s Director of Regulatory Affairs for Australia and New Zealand Dr Carolyn Tucek-Szabo about the launch of the new GSK PhD Graduate Innovation Program, supported by REDI over the next three years. The 12-month placement program, which builds on GSK’s successful Industry Based Learning program for undergraduate students, is open now for applications and will enable six PhD graduates to join GSK Australia assigning them to lead on core projects in areas such as early product development, medical affairs and regulatory affairs. The company is currently developing novel medicines in immuno-oncology, immuno-inflammatory, HIV, and infectious diseases (including COVID-19 therapy areas) so it’s an exciting time to throw off your lab coat to learn about industry career options. Apply by 2 December at GSK Australia’s website: https://au.gsk.com/en-au/careers/phd-graduates-and-post-doc-researchers/
Terms of Service
Do Not Sell My Personal Information
© Stitcher 2021